Site Search
Displaying results 361 - 370 of 573
Resource | Guidelines,
This policy brief provides an overview of key findings, data and figures of the new consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. In addition, it offers an overview of the comprehensive package on interventions and a table summarizing WHO recommendations concerning key populations.
Resource | Publications,
Nationally representative surveillance of HIVDR in populations initiating a standard triple-drug ART combination is critical to inform the selection of effective first-line ART combinations, as well as adequate pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) regimens.
The purpose of this survey is to calculate (a) a nationally representative prevalence estimate of HIVDR among all ART initiators, and (b) a nationally representative prevalence estimate of HIVDR among initiators without prior exposure to ARV drugs.
Resource | Publications,
How do we close the gap between the people moving forward and the people being left behind? This was the question we set out to answer in the UNAIDS Gap report. Similar to the Global report, the goal of the Gap report is to provide the best possible data, but, in addition, to give information and analysis on the people being left behind.
Too often people at higher risk of HIV infection face multiple issues—such as being a young woman displaced from home and living with HIV. Ensuring that no one is left behind means closing the gap between people can get services and people who can't, the people who are protected and the people who are punished.
Resource | Publications,
This concept note describes methods to assess nationally representative levels of viral load suppression and drug resistance in adults receiving ART through the implementation of a cross-sectional survey.
The main purpose of this survey is to calculate nationally representative prevalence estimates (with associated confidence intervals) of (1) VL suppression and (2) of HIVDR in populations receiving ART for 12 (±3) months and for ≥48 months.
Resource | Publications,
Evidence has emerged over the past few years on the effectiveness of antiretroviral-based prevention technologies to prevent (i) HIV transmission while decreasing morbidity and mortality in HIV-infected persons, and (ii) HIV acquisition in HIV-uninfected individuals through pre-exposure prophylaxis (PrEP).
This paper describes challenges for the implementation of antiretroviral-based prevention and makes the case that TasP and PrEP implementation research in Asia is much needed to provide insights into the feasibility of these interventions in populations where firm evidence of ‘real world’ effectiveness is still lacking.
Resource | Publications,
The action plan sets out a vision of a world in which there are no preventable deaths of newborns or stillbirths, where every pregnancy is wanted, every birth celebrated and women, babies and children survive, thrive and reach their full potential. Nearly 3 million lives could be saved each year if the actions in the plan are implemented and its goals and targets achieved.
Based on evidence of what works, and developed within the framework for Every Woman Every Child, the plan enhances and supports coordinated, comprehensive planning and implementation of newborn specific actions within the context of national reproductive, maternal, newborn, child and adolescent health (RMNCAH) strategies and action plans, and in collaboration with stakeholders from the private sector, civil society, professional associations and others. The goal is to achieve equitable and high quality coverage of care for all women and newborns through links with other global and national plans, measurement and accountability.
Resource | Publications,
The report is intended to provide information primarily for public health policy-makers and managers, and for the wider medical and public health community (including pharmaceutical companies), as a support for informing strategic actions and programme planning. It will also be of interest to the other sectors that are directly involved, including veterinary drug and animal husbandry, agriculture and aquaculture.
Resource | Publications,
The 2014–2015 biennium is critical in the fight against HIV: It is the culmination of a major global effort to achieve the health-related Millennium Development Goals (MDGs) and other global HIV goals and targets by 2015. Significant opportunities exist to build on progress to date and bring the world closer to its ultimate goal of ending the HIV pandemic.
The past decade produced some remarkable achievements. By the end of 2012, nearly 10 million people were receiving antiretroviral therapy (ART) in low- and middle-income countries. Universal access for all people in most urgent need of ART has been achieved in many countries, and the global target of ART for 15 million people by 2015 is within reach.
Resource | Reviews and Snapshots,
The report provides an overview of the patent landscape with respect to a select number of antiretroviral (ARV) medicines in developing countries as of April 2014. The focus is primarily on those ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.
Part 1 provides a brief introduction to patents and licences and their effect on the market for ARVs. It introduces key concepts that will facilitate an understanding of the report. It also explains which data sources were used for the report and notes a number of disclaimers with regard to the information contained in the report.
Part 2 is the core of the report. It outlines the patent status and licensing status of each ARV in the 81 developing countries for which data are available. For each ARV the report indicates whether that ARV is included in fixed-dose combinations for which there may be patents. General conclusions are drawn in light of the data. The key purpose is to provide an overview of the patent landscape for each ARV and, in particular, to show in which countries market competition for a given ARV is possible in view of existing patents and licences.
Resource | Publications,
In the case of mother-to-child transmission (MTCT) of both HIV and syphilis, testing pregnant women is a critical intervention for prevention, care and treatment of both mother and child. There are a number of combined HIV/ syphilis (treponemal) tests emerging that could be effective tools in the dual elimination of MTCT of HIV and syphilis. This document reviews the current testing landscape for such diagnostic tools.